Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12586835
Shah OJ, Ghosh S, Hunter T (2003) Mitotic regulation of ribosomal S6 kinase 1 involves Ser/Thr, Pro phosphorylation of consensus and non-consensus sites by Cdc2. J Biol Chem 278, 16433-42 12586835
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S394-p - p70S6K (human)
Modsite: TRQtPVDsPDDStLS SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S394‑p, p70S6K iso2 (human): S371‑p, p70S6K (mouse): S394‑p, p70S6K (rat): S394‑p, p70S6K iso2 (rat): S371‑p, p70S6K (fruit fly): S380‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  FT210 (breast cell), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) genetic knockout/knockin of upstream enzyme, pharmacological inhibitor of upstream enzyme

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  FT210 (breast cell), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole decrease

S434-p - p70S6K (human)
Modsite: sFEPKIRsPRRFIGs SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S434‑p, p70S6K iso2 (human): S411‑p, p70S6K (mouse): S434‑p, p70S6K (rat): S434‑p, p70S6K iso2 (rat): S411‑p, p70S6K (fruit fly): S418‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  FT210 (breast cell), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) genetic knockout/knockin of upstream enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
vanadate nocodazole inhibit treatment-induced increase
purvalanol nocodazole inhibit treatment-induced increase
seliciclib nocodazole inhibit treatment-induced increase
rapamycin nocodazole no effect upon treatment-induced increase
U0126 nocodazole no effect upon treatment-induced increase
PD98059 nocodazole no effect upon treatment-induced increase
SB202190 nocodazole no effect upon treatment-induced increase
wortmannin nocodazole no effect upon treatment-induced increase

T444-p - p70S6K (human)
Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  FT210 (breast cell), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
vanadate nocodazole inhibit treatment-induced increase
purvalanol nocodazole inhibit treatment-induced increase
seliciclib nocodazole inhibit treatment-induced increase
rapamycin nocodazole no effect upon treatment-induced increase
U0126 nocodazole no effect upon treatment-induced increase
PD98059 nocodazole no effect upon treatment-induced increase
SB202190 nocodazole no effect upon treatment-induced increase
wortmannin nocodazole no effect upon treatment-induced increase

S447-p - p70S6K (human)
Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  FT210 (breast cell), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) genetic knockout/knockin of upstream enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
vanadate nocodazole inhibit treatment-induced increase
purvalanol nocodazole inhibit treatment-induced increase
seliciclib nocodazole inhibit treatment-induced increase
rapamycin nocodazole no effect upon treatment-induced increase
U0126 nocodazole no effect upon treatment-induced increase
PD98059 nocodazole no effect upon treatment-induced increase
SB202190 nocodazole no effect upon treatment-induced increase
wortmannin nocodazole no effect upon treatment-induced increase

S240-p - S6 (human)
Modsite: RLssLRAstsKsEss SwissProt Entrez-Gene
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p, S6 (cow): S240‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  FT210 (breast cell), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole decrease

S244-p - S6 (human)
Modsite: LRAstsKsEssQK__ SwissProt Entrez-Gene
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p, S6 (cow): S244‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  FT210 (breast cell), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole decrease